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Abstract: Bepotastine besilate 1.5% solution is an H
1
-antihistamine recently approved by the 
Food and Drug Administration for the topical treatment of ocular itching associated with allergic 
conjunctivitis. Several clinical studies have demonstrated its safety as well as its efficacy versus 
placebo. This review finds that bepotastine besilate 1.5% solution is a suitable alternative to 
other agents within the class of H
1
-antihistamines, but there are no clinical trial data to suggest 
that it holds any specific advantages over other agents.
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Introduction
Ocular itching associated with allergic conjunctivitis is a common patient complaint, 
and up to 40% of the US population is affected by allergic conjunctivitis, according 
to epidemiologic surveys.1 Although there are masqueraders of allergic conjunctivitis, 
including bacterial etiologies that produce the common papillary conjunctival reaction, 
diagnosis is generally straightforward. Typical exam findings, including conjunctival 
injection and papillae, combined with standard complaints of seasonal- or exposure-
related ocular itching, lead to the clinical diagnosis. The disease begins with antigen 
exposure, which stimulates mast-cell degranulation, histamine release, and stimula-
tion of a downstream inflammatory cascade.2 Management of the condition depends 
on several considerations. First, an oral agent may be used when allergic rhinitis or 
another systemic symptom is also present. Even in this case, however, eye drops may 
be necessary to control the ocular itching, despite systemic therapy. Second, there are 
a number of ophthalmic drugs a vailable, with different mechanisms of action, dosing 
frequency, and tolerability. Finally, there is a wide range in price points for the vari-




-antihistamines include fexofenadine (Allegra® and Allegra-D®, 
p rescription [Rx] only), loratidine (Claritin® and others, over-the-counter [OTC]), deslora-
tidine (Clarinex®, Rx only), and cetirizine (Zyrtec®, OTC).3 Ophthalmic p reparations, 
which tend to have a more rapid onset than oral agents with respect to o cular itching,2 
include a number of drugs with antihistamine activity (H
1
-antagonists) and varying degrees 
of mast-cell stabilizing activity. These preparations include a zelastine (Optivar®, Rx only), 
epinastine (Elestat®, Rx only), ketotifen (Alaway®, Z aditor®, and others, OTC), and 
o lopatadine (Patanol®, Pataday®, Rx only) (see Table 1).4 Older agents that act primarily as 
mast-cell stabilizers are also available, including c romolyn (Crolom®,  Opticrom®, Rx only), 





n edocromil (Alocril®, Rx only), lodoxamide (Alomide®, 
Rx only), and pemirolast (Alamast®, Rx only).4 Bepotastine 
b esilate 1.5% (Bepreve®, ISTA P harmaceuticals, Rx only) is 
a recently US Food and Drug Administration (FDA)-approved 
ophthalmic H
1
-antihistamine, and the a vailable literature con-
cerning its use will be reviewed.
In addition to antihistamines and mast-cell stabilizing 
drugs, various ophthalmic corticosteroids are available for 
the treatment of allergic conjunctivitis. Their use is typically 
limited to severe disease due to their more impressive side 
effect profile, which generally includes cataract formation 
and elevation of intraocular pressure. One specific drug in 
this class deserves special mention. Loteprednol etabonate 
0.2% suspension is a topical ester corticosteroid2 that has 
been found to exhibit a low risk of intraocular pressure eleva-
tion over 4 weeks of therapy5 while reducing the symptoms 
of seasonal allergic conjunctivitis over a similar period of 
follow-up.6–8 Due to the combination of effectiveness and 
a low side effect profile, loteprednol may become a useful 
alternative to antihistamine therapy even in mild to moder-
ate allergic conjunctivitis, especially when prescribed as a 
short-term course. Other, more potent corticosteroids, such 
as prednisolone acetate 1% solution, will likely remain in 
use for more severe disease.
Bepotastine besilate 1.5% ophthalmic solution (Bepreve, 
Rx only) is an H
1
-antihistamine that was recently granted 
FDA approval as a new treatment for itching associated with 
allergic conjunctivitis. This drug was originally developed 
in Japan by Ube Industries, Ltd. and Tanabe Seiyaku Co., 
Ltd. and prepared as an oral medication for allergic rhinitis, 
receiving approval in Japan in July 2000.9 Development 
of the ophthalmic solution for US release was by ISTA 
 Pharmaceuticals, and approval was granted in 2009 based 
on data from Japanese development programs as well as two 
domestic conjunctival allergen challenge studies, including 
a single-site Phase II/III trial and a multisite Phase III study. 
Available data concerning the pharmacology, clinical use, 
and safety of this drug will be reviewed.
Review of pharmacology, mode  
of action, and pharmacokinetics
Bepreve, produced by ISTA Pharmaceuticals, is a clear, 
colorless to pale yellow solution containing bepotastine 
besilate as the active ingredient in a 1.5% solution, with a pH 
of 6.8 and osmolality of 290 mOsm/kg.9 This solution also 
contains benzalkonium chloride 0.005% as a preservative.9
Bepotastine is an H
1
-antihistamine and an inhibitor of his-
tamine release from mast cells.10 It is a piperidine derivative, 
similar to fexofenadine, ebastine, and loratidine.11 Multiple 
anti-inflammatory effects have been demonstrated, possibly 
as downstream mediators of the antihistamine activity. For 
example, in vitro studies suggest that bepotastine specifi-
cally suppresses proinflammatory cytokine production by 
keratinocytes, including inhibition of CD54 expression.12 
Recent work on guinea pigs showed that bepotastine, along 
with several other H
1
-antihistamines, reduces vascular hyper-
permeability in both antigen-induced and histamine-induced 
hyperpermeability models.13 This work also showed that 
bepotastine inhibits in vitro eosinophil chemotaxis induced 
by leukotriene B
4
, and pretreatment with bepotastine limits 
conjunctival eosinophil infiltration after topical platelet-
activating factor instillation.13
The pharmacokinetic properties of bepotastine as an oph-
thalmic solution are described in Phase I trial data from Japan, 
Table 1 Classes of ophthalmic agents to treat allergic conjunctivitis. Adapted with permission from PDR for Ophthalmic Medicines, 
37th edition, 2009
Generic name Product name(s) Class Doses/day
Azelastine HCl Optivar, generic H1-antagonist/mast-cell inhibitor 2
Bepotastine besilate Bepreve H1-antagonist/mast-cell inhibitor 2
Cromolyn sodium Crolom, generic Mast-cell inhibitor 4–6
emedastine difumarate emadine H1-antagonist 4
epinastine HCl elestat H1- and H2-antagonist/mast-cell inhibitor 2
Ketorolac tromethamine Acular, Acular LS, Acular PF Nonsteroidal anti-inflammatory drug 4
Ketotifen fumarate Alaway, Zaditor H1-antagonist/mast-cell inhibitor 2
Levocabastine HCl Livostin H1-antagonist 4
Lodoxamide tromethamine Alomide Mast-cell inhibitor 4
Loteprednol etabonate Alrex, Lotemax Corticosteroid 4
Naphazoline/antazoline vasocon-A Antihistamine/decongestant 4
Naphazoline/pheniramine Naphcon-A, Opcon-A, visine-A Antihistamine/decongestant 4
Nedocromil sodium Alocril H1-Antagonist/mast-cell inhibitor 2
Olopatadine HCl 0.1% Patanol H1-Antagonist/mast-cell inhibitor 2
Olopatadine HCl 0.2% Pataday H1-Antagonist/mast-cell inhibitor 1
Pemirolast potassium Alamast Mast-cell inhibitor 4
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and these will be described as reported in the FDA Office of 
Clinical Pharmacology review of the Japanese data.9 First, 
a repeated instillation study was performed, testing four-times-
a day dosing in both eyes for 7 days in 12 healthy adult male 
subjects, half of whom instilled bepotastine besilate 1.0% and 
half instilled the 1.5% formulation. Venous blood samples 
were measured by high-performance liquid chromatography 
and demonstrated a bepotastine plasma concentration peak 
1–2 hours postinstillation. The mean maximum c oncentration 
(Cmax) for the 1.5% group was 7.3 ± 1.9 ng/mL, which was 
much lower than the Cmax seen in the Phase I single oral 
dose trial, even at the lowest tested oral dose (Cmax was 
22.4 ± 2.1 ng/mL for the 2.5 mg oral dose). At the clinically 
relevant, approved Japanese oral dose of 10 mg, the Cmax 
was 101.3 ± 3.5 ng/mL, which is over 13 times higher than 
the Cmax seen in the repeated ophthalmic dosing trial. Thus, 
although there is systemic absorption of the ophthalmic drop, 
the plasma concentrations are quite low, minimizing the 
likelihood of systemic adverse effects. Furthermore, plasma 
concentrations at 24 hours postinstallation were below the 
quantifiable limit of 2 ng/mL in 11 of 12 subjects. In the oral 
single-dose study, 75%–90% of the administered dose was 
secreted in the urine as unchanged drug by 24 hours after 
administration within the 2.5–40 mg dose range.
An additional Phase I study addressed the metabolism 
of bepotastine by liver microsomes, showing that there was 
minimal metabolism by CYP3A4, CYP2C9, and CYP2C19, 
again as reported in English by the FDA Office of Clinical 
P harmacology review of the Japanese data.9 Within the 
r elevant concentration range, it was concluded that b epotastine 
would likely have no effects on c oncomitantly metabolized 
drugs involving these enzymes. Finally, a protein-binding 
Phase I study was performed, d emonstrating 55.4% mean 
plasma protein binding of the drug 1–2 hours after a 10 mg 
oral dose.9 This binding level was independent of plasma 
drug concentration.
Efficacy studies
There have been two randomized, double-masked, placebo-
controlled trials of bepotastine besilate ophthalmic solution 
as a treatment for ocular itching associated with allergic 
conjunctivitis.14,15 Both studies evaluated the effectiveness 
of the drug in comparison with its vehicle in a conjunctival 
allergen challenge (CAC) model. No comparative human 
clinical studies against other drugs have been performed, 
although bepotastine performed well compared with other 
H
1
-antihistamines in an experimental model of allergic 
c onjunctivitis in guinea pigs.13
The CAC model employed was consistent between the 
two studies.14,15 Subjects were included on the basis of age 
($10 years) and a positive skin-test reaction to an allergen 
within the prior 2 years. Further, during two screening visits, 
subjects had to demonstrate a positive reaction to the t esting 
protocol with respect to ocular itching and conjunctival 
r edness. Visit 1 (day-21) was used to determine the lowest 
dose of the defined antigen (from skin testing for that patient) 
that would elicit an ocular allergic response. Visit 2 (day-14) 
was dedicated to confirming this consistent allergic response. 
The primary outcome variables measured were subject-
evaluated ocular itching at 3, 5, and 7 minutes post-CAC 
(0–4 scale allowing half steps) and investigator-evaluated 
conjunctival redness at 7, 15, and 20 minutes post-CAC 
(0–4 scale allowing only whole steps).
Patients with validated responses to the CAC continued 
with the study protocol. At visit 3 A (day 0), patients were 
randomly assigned to bepotastine besilate 1.0% ophthalmic 
solution, bepotastine 1.5%, or inactive vehicle (placebo), and 
one drop of the appropriate solution was instilled in each eye. 
Subjects returned 16 hours later (visit 3B) for a CAC. This 
time period was chosen to correspond to a duration of action 
suitable for once-daily dosing. Primary as well as secondary 
outcome measures were obtained at stated intervals, with 
grading of allergic conjunctivitis over the next 20 minutes. 
Monitoring for adverse effects was also employed.
Visit 4 (day 14) was scheduled to give a 2-week 
w ashout of the study drug instilled on day 0. At this visit, 
the a ppropriate drug was again instilled, and a CAC was 
administered after 8 hours and its effects graded. This time 
period was chosen to correspond with a suitable duration of 
action for a drug intended to be dosed twice daily. Visit 5 
(day 28) was identical to visit 4, except CAC was adminis-
tered at 15  minutes after the drug instillation. This interval 
was chosen to evaluate for a rapid onset of drug activity.
The first study was a Phase II/III single-center CAC 
study that analyzed 107 subjects evenly divided among the 
three study groups.14 Analysis of the primary outcomes, 
ocular itching, and conjunctival redness was applied to 
the per-protocol (PP) population that excluded protocol 
v iolators and to the intention-to-treat (ITT) population 
using last observation carried forward (LOCF) for m issing 
data. Clinical significance was defined in the protocol 
as $1.0-unit between-group (placebo versus drug) differ-
ence between mean ocular itching or conjunctival redness 
at two of three time points at a study visit, and $0.5-unit 
mean difference at all time points. Statistical analysis of the 
conjunctival h yperemia data showed statistically significant 





 improvements in hyperemia scores for both c oncentrations 
of drug compared with placebo (0.2–0.8 U difference, 
depending on time point, for b epotastine 1% versus 
 placebo; -0.1–0.6 U difference for bepotastine 1.5%), but 
these improvements did not meet the predefined criteria for 
clinical significance. Ocular itching data, however, showed 
statistically and c linically significant improvements with 
both concentrations of bepotastine for the 15-minute (rapid 
onset of action) and 8-hour (twice-a-day dosing) CAC. 
Bepotastine 1.5% showed a similar effect at both of these 
time points (1.2–1.5 U for the 15-minute CAC, 1.2–1.7 U 
for the 8-hour CAC), but bepotastine 1.0% showed a drop-
off in the effect with the longer duration (1.3–1.4 U for the 
15-minute CAC, 0.9–1.1 U for the 8-hour test). B epotastine 
1.5% also d emonstrated a significant effect in clinical 
s ignificance for the 16-hour CAC (0.9–1.0 U).
The second efficacy study was a Phase III multicenter, 
prospective, double-masked, placebo-controlled, CAC 
clinical trial.15 This study enrolled 130 subjects at five 
clinical sites, dividing the subjects equitably between the 
three groups. Study methodology was identical to the single-
center trial, except ocular comfort was graded by the subject 
on a 4-point scale immediately after drop instillation and 
5 m inutes later. In this study, both concentrations of bepo-
tastine demonstrated at least a 1.2-unit reduction in ocular 
itching for the 15-minute and 8-hour CACs. Efficacy was 
significantly reduced for both concentrations at the 16-hour 
time point. A modest reduction in conjunctival redness was 
also seen, but only during the 15-minute CAC. There appears 
to have been a small decrease in ocular comfort for each drug 
concentration compared with placebo, although the measure 
approaches zero for all subjects at all time points, indicating 
relatively good ocular comfort on drug administration.
The FDA statistical analysis evaluated the robustness 
of the submitted efficacy data.16 The danger of using LOCF 
for missing data was explored, noting the potential b iasing 
of results with this method. Sensitivity analyses using 
a lternative population sets (PP and ITT with observed 
data only) and r epetition of the ITT analysis with different 
i mputation m ethods for missing data showed that bepotastine 
1.0% and 1.5% maintained a predefined standard of clinical 
s ignificance for ocular itching, satisfying this critique. 
In addition, the choice of p values for clinical significance 
evaluation was criticized for the lack of a multiplicity 
adjustment to account for the “majority of time points” 
stipulation that allows multiple ways to satisfy the clinical 
significance criteria. When these adjustments were made, 
however, the efficacy conclusions remained unchanged.
In summary, bepotastine 1.0% and 1.5% are found to 
be efficacious for the treatment of ocular itching related to 
allergic conjunctivitis, with a swift onset of action and appro-
priate duration of action for twice-a-day dosing. This drug 
does not appear to be sufficiently effective for the indication 
of conjunctival redness. Finally, bepotastine 1.5% solution 
was found to be more effective than the 1.0% concentration, 
so only the 1.5% concentration has been FDA approved.
Safety and tolerability
The side effect profile of bepotastine ophthalmic solution is 
s imilar to that of other ocular antihistamines, a list of u ncommon 
or low-risk events comprising headache, a sthenia, blurry vision, 
burning on drug instillation, cold and flu s ymptoms, cough, 
fatigue, dry eye, foreign body sensation, eyelid edema, keratitis, 
hyperemia, nausea, pharyngitis, pruritis, rhinitis, sinusitis, sore 
throat, and bitter taste.17 T olerability was reported for each of 
the randomized trials.14,15 In addition, an unpublished safety 
study was undertaken to evaluate only the 1.5% bepotastine 
concentration at six sites in the US, and this was completed with 
a randomized, double-masked, p lacebo-controlled, parallel-
group safety study design. Results of this study will be given 
as reported in FDA documents.16,17
In the single-site Phase II/III trial, the number of ocular 
adverse events reported was greater in the placebo group 
(8.3% of subjects) than in either treatment arm of the study, 
and all events were limited to eye irritation, foreign body 
sensation, and a single conjunctival cyst in the bepotastine 
1.5% group.14 Although a small number of nonocular adverse 
events were reported in all study groups, including placebo, 
only taste on instillation appears to be more common in the 
drug groups than in the placebo arm (20%–25% incidence in 
the two drug concentration groups versus 0% for placebo).14 
O cular and nonocular side effects were similar in the mul-
ticenter efficacy trial, revealing no new concerns, and in 
this instance a taste on instillation was only noted in 5% of 
subjects in the drug arms versus 0% in the placebo arm.15
The dedicated safety study for bepotastine 1.5% 
tested bilateral twice-a-day dosing for 6 weeks in healthy 
volunteers $3 years old.16,17 Six sites enrolled 861 healthy 
subjects, randomizing to a 2:1 active:vehicle ratio. 
The p opulation was predominantly Caucasian (85% of 
575 s ubjects in the bepotastine group and 84% of 286 s ubjects 
in the vehicle group), and females  outnumbered males .3:2. 
The pediatric population included 47 bepotastine and 
25 vehicle subjects in the 3–9 year age group, as well as 
40 bepotastine and 15 vehicle subjects in the 10–17 year age 
group. The study consisted of four visits over a pproximately 
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43 days, and subjects c ompleted a diary to document drug 
instillation. Any subject who completed .75% of sched-
uled doses was considered a study participant. Ninety-three 
percent of subjects (801 of 861) completed the entire study 
protocol. This study demonstrated the safety of bepotastine 
1.5% ophthalmic solution, with no deaths and no seri-
ous adverse events reported. There were 12 subjects who 
withdrew from the study due to an adverse event, six from 
the bepotastine group and six from the vehicle group. The 
adverse events that appeared to be potentially related to 
the study drug were eye irritation (4.7% bepotastine versus 
2.1% vehicle), taste perversion (14.6% versus 1.4%), bad 
taste (7.8% versus 0.3%), headache (3.5% versus 2.4%), 
and a variety of rarely reported nasal complaints (eg, nasal 
congestion, postnasal drip, sneezing). The most commonly 
reported adverse effect was a taste-related event in 25.2% 
of subjects, a result that was highly statistically significant.16 
Subjects taking bepotastine did not demonstrate any clinically 
significant change from baseline or compared with the vehicle 
in any other safety measurements, including endothelial cell 
counts, intraocular pressure, visual acuity, slit-lamp biomi-
croscopy, and dilated fundoscopy. In the 3–9 year age group 
subject population, only four adverse events were reported, 
all related to taste.17 The results for the 10–17 year age group 
were similarly encouraging, with six adverse events related 
to taste, one to headache, and one minor ocular complaint 
(compared with two similar ocular complaints in the vehicle 
group).17 Finally, there were no statistically significant dif-
ferences in ocular comfort between the study drug and its 
vehicle in this study.
It is noted that bepotastine has been available as an 
oral medication since 2000 in Japan. As reported in the 
FDA clinical review,17 Japanese postmarketing experience 
demonstrates an adverse event rate similar to that found 
during clinical studies prior to drug approval (9.47%), with 
the two most common events being drowsiness (1.32% of 
patients) and upper abdominal pain (0.13%). No other serious 
adverse events were demonstrated. A retrospective review 
of bepotastine oral tablets was also conducted in the pediat-
ric population (ages 5–14 years), and all confirmed events 
were found to be of the mild variety, including drowsiness 
(0.4%), thirst (0.2%), and urticaria (0.2%). A comparison 
study in healthy adults showed that bepotastine had a low 
rate of sedation even among a group of later-generation 
H
1
-antihistamines.18 According to a large patient survey, the 
sedative effects of oral bepotastine appear to be in line with 
other second-generation H
1
-antihistamines when evaluated 
using a visual analog scale.19
In summary, over a 6-week time period, twice-daily 
b epotastine besilate 1.5% ophthalmic solution was found 
to be a safe drug for subjects $3 years old when dosed 
bilaterally. No serious adverse events were observed, 
although abnormal taste complaints were common, found 
in approximately 25% of subjects across studies. Ocular 
comfort does not appear to be compromised by bepotastine. 
Although drowsiness is a common complaint due to systemic 
H
1
-antihistamines, this was not seen after ophthalmic dosing. 
Finally, bepotastine ophthalmic solution has not been tested 
in children under 3 years old or in pregnant women.
Patient-focused perspectives
The recent FDA approval and commercial availability of 
bepotastine besilate 1.5% ophthalmic solution adds to the 
array of treatments available for ocular itching associated 
with allergic conjunctivitis. Although this drug has not been 
directly compared with other available treatments, studies 
to date prove its effectiveness as well as its mild side effect 
profile. The twice-daily dosing strategy, although less opti-
mal than the once-daily formulation of olopatadine 0.2% 
(Pataday), should lend itself to reasonable adherence and is 
identical to the dosing of azelastine, epinastine, ketotifen, 
and the 0.1% solution of olopatadine.
A key disadvantage to bepotastine is that its formulation, 
like most other drugs for this condition, contains benzalko-
nium chloride, which can be absorbed by contact lenses 
and is an ocular irritant to which certain patients may be 
allergic. It is recommended that contact lenses be removed 
prior to instillation of this agent. There are no preservative-
free f ormulations of ophthalmic H
1
-antihistamines, so this 
drawback does not distinguish bepotastine.
The expense of the various ophthalmic H
1
-antihistamines 
is displayed in Table 2, with a column showing the price per 
day of bilateral treatment with each agent. Calculating based 
on retail costs, the over-the-counter ketotifen formulations 
are clearly the least expensive options within this class, 
with daily expenses of $0.26 (Alaway) or $0.56 (Zaditor). 
For patients who do not respond to ketotifen or who are 
unable to tolerate the formulations of these agents, generic 
azelastine bepotastine is the next least expensive ophthalmic 
H
1
- antihistamine, at $3.20 per day of therapy. The least 
expensive on-patent H
1
-antihistamine formulation is bepo-
tastine 1.5%, at $3.55 per day. This compares quite favorably 
with other on-patent prescription agents, such as olopatadine 
0.1% ($4.66/day) and olopatadine 0.2% ($4.49/day).
Bottle size may be another advantage of bepotastine, 
which is marketed as a 10 mL volume. As the days/bottle 





column in Table 2 displays, this provides approximately 
50.1 days of therapy in a single bottle, which is equal to the 
largest size of ketotifen and longer than any other agent. This 
length of time may encompass the entire season of allergic 
conjunctivitis for some patients who display symptoms in 
only part of the year. These patients would only need to 
purchase a single bottle of bepotastine each year, which is a 
distinct efficiency advantage over smaller bottle sizes.
Conclusion
A review of the available literature regarding bepotastine 
besilate 1.5% ophthalmic solution (Bepreve) confirms that it 
is a safe and effective agent for the treatment of ocular i tching 
associated with allergic conjunctivitis. This agent does not 
eliminate conjunctival redness, and it should not be used 
in children under 3 years old or in pregnant women. Aside 
from these concerns, bepotastine could be widely prescribed 
and should prove to be an effective alternative to available 
therapies, although there are no comparative clinical data to 
demonstrate any difference in effectiveness between bepo-
tastine and other ophthalmic H
1
-antihistamines. Although the 
price point for bepotastine is higher than the over-the-counter 
ketotifen formulations, the current retail price is lower on a 
per-day-of-therapy basis than the retail price of any other 
on-patent drugs within bepotastine’s class. Providers should 
feel confident in prescribing bepotastine for ocular itching 
associated with allergic conjunctivitis, especially for patients 
who have failed less expensive alternatives.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunol Allergy 
Clin North Am. 2008;28:43–58.
 2. Bepotastine (Bepreve): an ophthalmic H1-antihistamine. Med Lett 
Drugs Ther. 2010;52:11–12.
 3. Bielory L. Ocular allergy treatment. Immunol Allergy Clin North Am. 
2008;28:189–224.
 4. Physicians’ Desk Reference for Ophthalmic Medicines. Montvale, NJ: 
Thomson Reuters; 2008:282.
 5. Bartlett JD, Howes JF, Ghormley NR, et al. Safety and efficacy of 
loteprednol etabonate for treatment of papillae in contact lens-associated 
giant papillary conjunctivitis. Curr Eye Res. 1993;12:313–321.
 6. Dell SJ, Lowry GM, Northcutt JA, et al. A randomized, double-masked, 
placebo-controlled parallel study of 0.2% loteprednol etabonate in 
patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol. 
1998;102:251–255.
 7. Dell SJ, Shulman DG, Lowry GM, Howes J. A controlled  evaluation 
of the efficacy and safety of loteprednol etabonate in the prophy-
lactic treatment of seasonal allergic conjunctivitis. Loteprednol 
Allergic Conjunctivitis Study Group. Am J Ophthalmol. 1997;123: 
791–797.
 8. Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, double-
masked, placebo-controlled parallel study of loteprednol etabonate 
0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology. 
1999;106:362–369.
 9. Bergman K, Bonapace C. Clinical Pharmacology Review of Bepotastine 
Besilate Ophthalmic Solution 1.5%. FDA, ed. 2009.
 10. Hussar DA, Abbas CA. New drugs: asenapine, iloperidone, and bepo-
tastine besilate. J Am Pharm Assoc (2003). 2010;50:107–110.
 11. Inomata N, Tatewaki S, Ikezawa Z. Multiple H1-antihistamine-induced 
urticaria. J Dermatol. 2009;36:224–227.
 12. Kobayashi M, Kabashima K, Nakamura M, Tokura Y.  Downmodulatory 
effects of the antihistaminic drug bepotastine on cytokine/chemokine 
 production and CD54 expression in human keratinocytes. Skin  Pharmacol 
Physiol. 2009;22:45–48.
Table 2 Retail price data for ophthalmic H1-antihistamines for relief of seasonal allergic conjunctivitis. Adapted with permission from 





OTC? Doses/day Bottle  
sizea (mL)




Azelastine HCl Optivar No 2 6 $115.99109.06 $0.98 $3.88 30.6
Generic No 2 6 $95.99 $0.80 $3.20 30.6
Bepotastine  
besilate
Bepreve No 2 10 $177.31104.99 $0.90 $3.55 50.1
emedastine  
difumarate
emadine No 4 5 $78.75 $0.79 $6.30 12.5
epinastine HCl elestat No 2 5 $116.58 $1.17 $4.66 25.5
Ketotifen  
fumarate
Alaway Yes 2 10 $12.99 $0.06 $0.26 50.1
Zaditor Yes 2 5 $13.99 $0.14 $0.56 25.5
Nedocromil  
sodium
Alocril No 2 5 $93.01 $0.93 $3.72 25.5
Olopatadine  
HCl 0.1%
Patanol No 2 5 $116.39106.80 $1.16 $4.66 25.5
Olopatadine  
HCl 0.2%
Pataday No 1 2.5 $112.20105.84 $2.24 $4.49 25.5
Notes: aLargest available bottle size used for calculations; b20 drops/mL assumed.
Abbreviation: OTC, over-the-counter.
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